^
CANCER:

Ganglioglioma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
BRAF V600E
Ganglioglioma
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
vemurafenib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
cobimetinib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
trametinib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
dabrafenib
Sensitive
:
A2
BRAF V600
Ganglioglioma
vemurafenib
Sensitive
:
C1
BRAF V600
Ganglioglioma
trametinib + dabrafenib
Sensitive
:
C1
BRAF V600
Ganglioglioma
vemurafenib + cobimetinib
Sensitive
:
C1
BRAF V600
Ganglioglioma
BRAF inhibitor + MEK inhibitor
Sensitive
:
C3
BRAF T599
Ganglioglioma
trametinib + dabrafenib
Sensitive
:
C4